Skip to main content

Table 3 Dosimetry differences between ART and phantom non-ART plans in various target volumes and organs at risk (n = 40)

From: Which nasopharyngeal cancer patients need adaptive radiotherapy?

Variables ART* (Gy; mean ± SD) Phantom plan (Gy; mean ± SD) Change (%) p-value
PTV-1, D98 15.4 ± 1.6 12.3 ± 3.7 20.1 <  0.000
PTV-1, D95 15.6 ± 1.6 13.8 ± 3.2 13.0 0.001
PTV-1, D50 16.0 ± 1.7 15.9 ± 1.6 0.6 0.071
Brainstem, D2 6.6 ± 1.8 6.6 ± 1.7 −0.0 0.990
Cord, Dmax 6.0 ± 1.3 6.4 ± 1.4 −6.3 0.243
Chiasm, Dmax 1.8 ± 2.0 2.1 ± 2.8 −16.5 0.241
Chiasm, Dmean 1.3 ± 1.3 1.5 ± 2.2 −13.3 0.285
Optic N, Dmax 2.3 ± 2.9 2.6 ± 3.5 −13.0 0.390
Optic N, Dmean 1.0 ± 0.8 1.2 ± 1.2 −20.0 0.282
Cochlear, Dmax 8.3 ± 2.8 8.6 ± 2.7 −3.6 0.501
Cochlear, Dmean 6.1 ± 2.0 6.0 ± 2.0 1.7 0.899
Parotid-1, Dmean 5.3 ± 1.6 6.0 ± 2.3 −11.7 0.004
Parotid-2, Dmean 4.2 ± 1.3 4.3 ± 1.4 −2.3 0.617
  1. *Mean ART PTV-1 prescribed dose = 15.6 ± 1.6 Gy
  2. Abbreviations: ART adaptive radiotherapy, Dx dose to x% of the target volume Dmax maximal dose, Dmean mean dose, parotid-1 ipsilateral parotid glands, parotid-2 contralateral parotid glands